ImmunoCellular shares plummet after PhII flop; Merck resumes supplying Zostavax to U.K.;

> The failure of ImmunoCellular's ($IMUC) brain cancer vaccine to meet a key Phase II endpoint caused the company's share price to halve in after-hours trading. Item

> Merck ($MRK) has resumed supplying shingles vaccine Zostavax to the U.K. after months of delays. Post

> Slow uptake is threatening to undermine the addition of flu vaccines to the U.K. childhood immunization schedule. News

> Ireland is continuing to pay the medical expenses of people who developed narcolepsy after receiving GlaxoSmithKline's ($GSK) swine flu vaccine. Article

> Ascend Biopharmaceuticals has partnered with 3M ($MMM) to develop a cancer vaccine. Piece

> A lack of knowledge about HPV vaccines is limiting uptake among racial minorities. Release

> Indian politicians continue to call for a ban on the pentavalent vaccine. Item

> The U.S. sustained its elimination of endemic measles and rubella through to 2011. Study

> A Pakistani scholar known as the "Father of the Taliban" has backed use of polio vaccines. Report

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.